Overview

A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

Status:
RECRUITING
Trial end date:
2028-12-14
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess BMS-986500 as monotherapy in advanced solid tumors and as combination therapy in CDK4/6 inhibitor pre-treated advanced breast cancer.
Phase:
PHASE1
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Fulvestrant
palbociclib